{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T18:07:24Z","timestamp":1791223644751,"version":"4.1.0"},"reference-count":24,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,3,27]]},"DOI":"10.1097\/qad.0b013e32835cee6e","type":"journal-article","created":{"date-parts":[[2012,12,4]],"date-time":"2012-12-04T19:12:29Z","timestamp":1354648349000},"page":"939-950","source":"Crossref","is-referenced-by-count":118,"title":["Week 96 efficacy and safety of rilpivirine in treatment-naive, HIV-1 patients in two Phase III randomized trials"],"prefix":"10.1097","volume":"27","author":[{"given":"Calvin J.","family":"Cohen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Michel","family":"Molina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Cassetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ploenchan","family":"Chetchotisakd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriano","family":"Lazzarin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chloe","family":"Orkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Rhame","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans-J\u00fcrgen","family":"Stellbrink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taisheng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herta","family":"Crauwels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence","family":"Rimsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Vanveggel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katia","family":"Boven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R2-10-20210130","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1001\/jama.2012.7961","article-title":"Antiretroviral treatment of adult HIV infection 2012 Recommendations of the International AIDS Society: USA Panel.","volume":"308","author":"Thompson","year":"2012","journal-title":"JAMA"},{"key":"R4-10-20210130","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1310\/3Q91-YT2D-BUT4-8HN6","article-title":"Safety and tolerance of efavirenz in different antiretroviral regimens: results from a national multicenter prospective study in 1,033 HIV-infected patients.","volume":"3","author":"Perez-Molina","year":"2002","journal-title":"HIV Clin Trials"},{"key":"R5-10-20210130","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1016\/S0140-6736(04)15997-7","article-title":"Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study.","volume":"363","author":"van Leth","year":"2004","journal-title":"Lancet"},{"key":"R6-10-20210130","doi-asserted-by":"crossref","first-page":"e19","DOI":"10.1371\/journal.pmed.0010019","article-title":"Nevirapine and efavirenz elicit different changes in lipid profiles in antiretroviral-therapy-naive patients infected with HIV-1.","volume":"1","author":"van Leth","year":"2004","journal-title":"PLoS Med"},{"key":"R7-10-20210130","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1310\/hct1001-1","article-title":"Effects of first-line use of nucleoside analogues, efavirenz, and ritonavir-boosted protease inhibitors on lipid levels.","volume":"10","author":"Hill","year":"2009","journal-title":"HIV Clin Trials"},{"key":"R8-10-20210130","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.antiviral.2010.03.001","article-title":"The frequency and reasons for antiretroviral switching with specific antiretroviral associations: the SWITCH study.","volume":"86","author":"Davidson","year":"2010","journal-title":"Antiviral Res"},{"key":"R9-10-20210130","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1089\/aid.2005.21.743","article-title":"Reasons for stopping antiretrovirals used in an initial highly active antiretroviral regimen: increased incidence of stopping due to toxicity or patientphysician choice in patients with hepatitis C coinfection.","volume":"21","author":"Mocroft","year":"2005","journal-title":"AIDS Res Hum Retroviruses"},{"key":"R10-10-20210130","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1097\/00126334-200312010-00008","article-title":"Patterns and correlates of discontinuation of the initial HAART regimen in an urban outpatient cohort.","volume":"34","author":"OBrien","year":"2003","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R16-10-20210130","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1097\/QAI.0b013e31824d006e","article-title":"Efficacy and safety of rilpivirine (TMC278) versus efavirenz at 48 weeks in treatment-naive, HIV-1-infected patients: pooled results from the phase 3 double-blind, randomized ECHO and THRIVE trials.","volume":"60","author":"Cohen","year":"2012","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R17-10-20210130","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0140-6736(11)60983-5","article-title":"Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, noninferiority trial.","volume":"378","author":"Cohen","year":"2011","journal-title":"Lancet"},{"key":"R18-10-20210130","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/S0140-6736(11)60936-7","article-title":"Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial.","volume":"378","author":"Molina","year":"2011","journal-title":"Lancet"},{"key":"R19-10-20210130","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1097\/QAI.0b013e31823df4da","article-title":"Genotypic and phenotypic characterization of HIV-1 isolates obtained from patients on rilpivirine therapy experiencing virologic failure in the phase 3 ECHO and THRIVE studies: 48-week analysis.","volume":"59","author":"Rimsky","year":"2012","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R21-10-20210130","doi-asserted-by":"crossref","first-page":"e22871","DOI":"10.1371\/journal.pone.0022871","article-title":"Statistical methods in recent HIV noninferiority trials: reanalysis of 11 trials.","volume":"6","author":"Flandre","year":"2011","journal-title":"PLoS ONE"},{"key":"R25-10-20210130","first-page":"138","article-title":"Update of the drug resistance mutations in HIV-1: December 2009.","volume":"17","author":"Johnson","year":"2009","journal-title":"Top HIV Med"},{"key":"R26-10-20210130","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1001\/jama.292.2.191","article-title":"Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial.","volume":"292","author":"Gallant","year":"2004","journal-title":"JAMA"},{"key":"R28-10-20210130","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1097\/QAI.0b013e3181da1287","article-title":"Raltegravir versus efavirenz regimens in treatment-naive HIV-1-infected patients: 96-week efficacy, durability, subgroup, safety, and metabolic analyses.","volume":"55","author":"Lennox","year":"2010","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R29-10-20210130","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1310\/hct1103-125","article-title":"Efficacy and safety of maraviroc versus efavirenz, both with zidovudinelamivudine: 96-week results from the MERIT study.","volume":"11","author":"Sierra-Madero","year":"2010","journal-title":"HIV Clin Trials"},{"key":"R30-10-20210130","doi-asserted-by":"crossref","first-page":"445","DOI":"10.7326\/0003-4819-154-7-201104050-00316","article-title":"Atazanavir plus ritonavir or efavirenz as part of a 3-drug regimen for initial treatment of HIV-1.","volume":"154","author":"Daar","year":"2011","journal-title":"Ann Intern Med"},{"key":"R31-10-20210130","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1128\/AAC.00986-09","article-title":"TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1.","volume":"54","author":"Azijn","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"R32-10-20210130","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1097\/QAI.0b013e31823aca74","article-title":"The HIV-1 reverse transcriptase M184I mutation enhances the E128K-associated resistance to rilpivirine and decreases viral fitness.","volume":"59","author":"Kulkarni","year":"2012","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R33-10-20210130","doi-asserted-by":"crossref","first-page":"11300","DOI":"10.1128\/JVI.05584-11","article-title":"Compensation by the E138K mutation in HIV-1 reverse transcriptase for deficits in viral replication capacity and enzyme processivity associated with the M184IV mutations.","volume":"85","author":"Xu","year":"2011","journal-title":"J Virol"},{"key":"R34-10-20210130","doi-asserted-by":"crossref","first-page":"11309","DOI":"10.1128\/JVI.05578-11","article-title":"Interaction of reverse transcriptase (RT) mutations conferring resistance to lamivudine and etravirine: effects on fitness and RT activity of human immunodeficiency virus type 1.","volume":"85","author":"Hu","year":"2011","journal-title":"J Virol"},{"key":"R35-10-20210130","doi-asserted-by":"crossref","first-page":"4087","DOI":"10.1128\/AAC.00816-06","article-title":"In vitro human immunodeficiency virus type 1 resistance selections with combinations of tenofovir and emtricitabine or abacavir and lamivudine.","volume":"50","author":"Margot","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"R36-10-20210130","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1111\/j.1468-1293.2008.00644.x","article-title":"Impact of reverse transcriptase resistance on the efficacy of TMC125 (etravirine) with two nucleoside reverse transcriptase inhibitors in protease inhibitor-naive, nonnucleoside reverse transcriptase inhibitor-experienced patients: study TMC125-C227.","volume":"9","author":"Ruxrungtham","year":"2008","journal-title":"HIV Med"}],"container-title":["AIDS"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/journals.lww.com\/00002030-201303270-00010","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,2]],"date-time":"2024-05-02T15:53:21Z","timestamp":1714665201000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00002030-201303270-00010"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,3,27]]},"references-count":24,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2013]]}},"URL":"https:\/\/doi.org\/10.1097\/qad.0b013e32835cee6e","relation":{},"ISSN":["0269-9370"],"issn-type":[{"value":"0269-9370","type":"print"}],"subject":[],"published":{"date-parts":[[2013,3,27]]}}}